FINEARTS-HF: Improving outcomes in heart failure with preserved or mildly reduced ejection fraction

Cleve Clin J Med. 2026 May 1;93(5):273-277. doi: 10.3949/ccjm.93a.25081.

Abstract

The FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure, N Engl J Med 2024; 391(16):1475-1485) trial evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in patients with left ventricular ejection fraction 40% or greater. Finerenone reduced the composite risk of hospitalization for heart failure or cardiovascular death by 16% relative to placebo (rate ratio 0.84, P = .007), primarily by lowering admissions for heart failure. Finerenone is the first mineralocorticoid receptor antagonist to improve outcomes in this patient population.

Publication types

  • Review

MeSH terms

  • Aged
  • Female
  • Heart Failure* / drug therapy
  • Heart Failure* / mortality
  • Heart Failure* / physiopathology
  • Hospitalization / statistics & numerical data
  • Humans
  • Male
  • Mineralocorticoid Receptor Antagonists* / therapeutic use
  • Naphthyridines
  • Randomized Controlled Trials as Topic
  • Stroke Volume* / drug effects
  • Treatment Outcome

Substances

  • Mineralocorticoid Receptor Antagonists
  • finerenone
  • Naphthyridines